A statement released earlier today by Peel Hunt about Genedrive Plc (LON:GDR) holds the target price at 200.00GBX
- Updated: September 25, 2016
Genedrive Plc (LON:GDR) had its target price hold steady to 200.00GBX by Peel Hunt in a report released 09/21/2016. The new target price indicates a possible upside of 2.33% from the company's most recent close.
Boasting a price of 60.00GBX, Genedrive Plc (LON:GDR) traded 0.00% even on the day. With the last close down -26.78% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Genedrive Plc has recorded a 50-day average of 74.66GBX and a two hundred day average of 86.04GBX. Volume of trade was down over the average, with 1,050 shares of GDR changing hands under the typical 4,266
With a total market value of 0 GBX, Genedrive Plc has with a one year low of 50.00GBX and a one year high of 195.00GBX .
Brief Synopsis About Genedrive Plc (LON:GDR)
Genedrive plc, formerly Epistem Holdings plc, is a United Kingdom-based molecular diagnostics company. The Company is engaged in developing a point of need or point of care diagnostics platform for the diagnosis of infectious diseases, and for use in patient stratification (genotyping), pathogen detection and other indications. It has two segments: Preclinical Research Services and Personalised medicine. It offers Genedrive platform and tuberculosis or rifampicin resistance (MTB/RIF) test in India. The Genedrive molecular diagnostic system is a genotyping and sequence analysis device. The Preclinical Research Services division delivers preclinical services, testing efficacy and specificity of client drugs. The Personalised Medicine division focuses on advances in molecular technology to identify and develop diagnostic tests and biomarkers for use on its Genedrive diagnostic platform or in collaboration with drug development partners. The Company focuses on Novel Therapies division.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.